Veracyte Stock Today
| VCYT Stock | USD 18.86 0.06 0.32% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Veracyte is selling for under 18.86 as of the 18th of April 2024; that is -0.32% down since the beginning of the trading day. The stock's last reported lowest price was 18.74. Veracyte has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Veracyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of April 2022 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of October 2013 | Category Healthcare | Classification Health Care |
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. The company has 75.07 M outstanding shares of which 3.64 M shares are at this time shorted by private and institutional investors with about 4.98 trading days to cover. More on Veracyte
Moving together with Veracyte Stock
| 0.63 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Veracyte Stock
| 0.79 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.61 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.54 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.51 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.48 | ZNTL | Zentalis PharmaceuticalsL Financial Report 8th of May 2024 | PairCorr |
| 0.47 | MRSN | Mersana Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.41 | INZY | Inozyme PharmaInc Financial Report 14th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 2nd of May 2024
Veracyte Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Veracyte's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Veracyte or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Bonnie Anderson | ||||
| Thematic Idea | Healthcare (View all Themes) | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Veracyte report their recommendations after researching Veracyte's financial statements, talking to executives and customers, or listening in on Veracyte's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Veracyte. The Veracyte consensus assessment is calculated by taking the average forecast from all of the analysts covering Veracyte. | |||||
Veracyte's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Veracyte's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Veracyte's financial leverage. It provides some insight into what part of Veracyte's total assets is financed by creditors.
| |||||
Veracyte (VCYT) is traded on NASDAQ Exchange in USA. It is located in 6000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 815 people. Veracyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.45 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Veracyte's market, we take the total number of its shares issued and multiply it by Veracyte's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Veracyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 75.07 M outstanding shares of which 3.64 M shares are at this time shorted by private and institutional investors with about 4.98 trading days to cover.
Veracyte currently holds about 170.11 M in cash with 44.22 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Check Veracyte Probability Of Bankruptcy
Ownership AllocationVeracyte shows a total of 75.07 Million outstanding shares. The majority of Veracyte outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Veracyte to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Veracyte. Please pay attention to any change in the institutional holdings of Veracyte as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Veracyte Ownership Details
Veracyte Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Veracyte jumping above the current price in 90 days from now is about 98.0%. The Veracyte probability density function shows the probability of Veracyte stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.1687. This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Veracyte will likely underperform. Additionally, veracyte has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Veracyte to move above the current price in 90 days from now is about 98.0 (This Veracyte probability density function shows the probability of Veracyte Stock to fall within a particular range of prices over 90 days) .
Veracyte Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Veracyte that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Veracyte's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Veracyte's value.| Instituion | Recorded On | Shares | |
| Champlain Investment Partners, Llc | 2023-12-31 | 2.2 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1.6 M | |
| Gw&k Investment Management, Llc | 2023-12-31 | 1.4 M | |
| Nuveen Asset Management, Llc | 2023-12-31 | 1 M | |
| Northern Trust Corp | 2023-12-31 | 979.8 K | |
| Fisher Asset Management, Llc | 2023-12-31 | 875.2 K | |
| Granite Investment Partners, Llc | 2023-12-31 | 873.3 K | |
| Bank Of America Corp | 2023-12-31 | 839.5 K | |
| New York State Common Retirement Fund | 2023-12-31 | 837.5 K | |
| Ark Investment Management Llc | 2023-12-31 | 7.7 M | |
| Blackrock Inc | 2023-12-31 | 7.2 M |
Veracyte Historical Income Statement
Veracyte Income Statement is one of the three primary financial statements used for reporting Veracyte's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Veracyte revenue and expense. Veracyte Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Veracyte's Cost Of Revenue is comparatively stable compared to the past year. Total Operating Expenses is likely to gain to about 247 M in 2024, whereas EBIT is likely to drop (12.7 M) in 2024. View More FundamentalsVeracyte Stock Against Markets
Picking the right benchmark for Veracyte stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Veracyte stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Veracyte is critical whether you are bullish or bearish towards Veracyte at a given time. Please also check how Veracyte's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Veracyte without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Dashboard Now
Portfolio DashboardPortfolio dashboard that provides centralized access to all your investments |
| All Next | Launch Module |
Veracyte Corporate Directors
Veracyte corporate directors refer to members of a Veracyte board of directors. The board of directors generally takes responsibility for the Veracyte's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Veracyte's board members must vote for the resolution. The Veracyte board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Robert Epstein | Director | Profile | |
| Kevin Gordon | Director | Profile | |
| Karin Eastham | Director | Profile | |
| Evan Jones | Director | Profile |
How to buy Veracyte Stock?
Before investing in Veracyte, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Veracyte. To buy Veracyte stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Veracyte. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Veracyte stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Veracyte stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Veracyte stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Veracyte, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.
Already Invested in Veracyte?
The danger of trading Veracyte is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Veracyte is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Veracyte. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Veracyte is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Veracyte is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Veracyte Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Veracyte Stock. Highlighted below are key reports to facilitate an investment decision about Veracyte Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Veracyte. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Veracyte Stock please use our How to Invest in Veracyte guide.You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Veracyte Stock analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |
Is Veracyte's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Veracyte. If investors know Veracyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Veracyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.02) | Revenue Per Share 4.97 | Quarterly Revenue Growth 0.223 | Return On Assets (0.01) | Return On Equity (0.07) |
The market value of Veracyte is measured differently than its book value, which is the value of Veracyte that is recorded on the company's balance sheet. Investors also form their own opinion of Veracyte's value that differs from its market value or its book value, called intrinsic value, which is Veracyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Veracyte's market value can be influenced by many factors that don't directly affect Veracyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Veracyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Veracyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Veracyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.